Ranjana Advani, Other is a Internal Medicine Physician - Hematology practicing in Palo Alto, CA
She has not yet shared a personalized biography with Doctor.com.
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Butler University in Indianapolis | Medical Degree | Not Specified | |
| Bombay University, K.J. Somaiya Medical College And Research Centre | Medical Degree | 1982 | |
| Grant Government Medical College | Medical Degree | 1982 |
| Institution | Focus | Year |
|---|---|---|
| Internship - Santa Clara Valley Medical Center | 1987 | |
| Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 1996 | |
| Residency - Stanford University Program | Not Specified | |
| Residency - Stanford University School of Medicine | 1990 |
| Certification | Cert. Body | Year |
|---|---|---|
Sub-Specialty: Medical Oncology | Internal Medicine | 1995 |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | Leukemia & lymphoma | Bevacizumab and cyclosphosphamide, doxorubicin | 2014 |
| Other Publication | Jourl of clinical oncology | Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte | 2014 |
| Other Publication | Blood | Phase 2 study of VcR-CVAD with maintence rituximab for untreated mantle cell lymphoma | 2014 |
| Other Publication | NEW ENGLAND JOURL OF MEDICINE | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma | 2013 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Targeted Therapy in Relapsed Classical Hodgkin Lymphoma | 2013 |
| Other Publication | Blood | Plasma Epstein-Barr virus D predicts outcome in advanced Hodgkin lymphoma | 2013 |
| Other Publication | NEW ENGLAND JOURL OF MEDICINE | Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastil B-Cell Lymphoma | 2013 |
| Other Publication | ANLS OF ONCOLOGY | Efficacy of abbreviated Stanford V chemotherapy | 2013 |
| Other Publication | BRITISH JOURL OF HAEMATOLOGY | The efficacy and tolerability of adriamycin, bleomycin | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Bruton Tyrosine Kise Inhibitor Ibrutinib | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin | 2012 |
| Other Publication | ONCOLOGIST | Brentuximab Vedotin in Transplant-ive Patients with Relapsed or Refractory Hodgkin Lymphoma | 2012 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Brentuximab Vedotin | 2012 |
| Other Publication | LEUKEMIA & LYMPHOMA | Cardiac toxicity associated with bevacizumab | 2012 |
| Other Publication | INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS | 2011 |
| Other Publication | CLINICAL CANCER RESEARCH | MicroRs Are Independent Predictors of Outcome in Diffuse Large B | 2011 |
| Other Publication | LEUKEMIA & LYMPHOMA | Current concepts and controversies in the magement of early stage Hodgkin lymphoma | 2011 |
| Other Publication | Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. | Comparison of conventiol prognostic indices in patients older than 60 years with diffuse large B | 2010 |
| Other Publication | EXPERT REVIEW OF ANTICANCER THERAPY | Risk stratification in extranodal tural killer/T-cell lymphoma | 2010 |
| Other Publication | LANCET ONCOLOGY | Magement of T-cell and tural-killer-cell neoplasms in Asia | 2009 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Phase I Study of the Humanized Anti | 2009 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Impact of positive positron emission tomography | 2007 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy | 2004 |
| Other Publication | BRITISH JOURL OF HAEMATOLOGY | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era | 2014 |
| Other Publication | LEUKEMIA & LYMPHOMA | A multicenter phase II trial to determine the safety | 2013 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines | 2013 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphomas, version 1.2013. | 2013 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Gene Expression-Based Model Using Formalin-Fixed Paraffin | 2013 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's Lymphomas, version 3.2012. | 2012 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines | 2012 |
| Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines | 2012 |
| Other Publication | BLOOD | In situ vaccition against mycosis fungoides by intratumoral injection of a TLR9 | 2012 |
| Other Publication | INVESTIGATIOL NEW DRUGS | Phase I trial of oblimersen (GesenseA (R)) and gemcitabine in refractory and advanced maligncies | 2011 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin lymphoma. | 2011 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma | 2011 |
| Other Publication | OBSTETRICS AND GYNECOLOGY | Lymphoma in Pregncy Initially Diagnosed as Vagil Intraepithelial Neoplasia and Lichen Planus | 2011 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2011 |
| Other Publication | JOURL OF THE AMERICAN COLLEGE OF RADIOLOGY | ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II | 2011 |
| Other Publication | SCIENCE TRANSLATIOL MEDICINE | CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma | 2011 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study | 2010 |
| Other Publication | JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2010 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. | 2010 |
| Other Publication | BRITISH JOURL OF HAEMATOLOGY | Lymphoma cell VEGFR2 expression detected | 2010 |
| Other Publication | CURRENT OPINION IN ONCOLOGY | The emerging role for rituximab in the treatment of nodular lymphocyte predomint Hodgkin lymphoma | 2009 |
| Other Publication | ARCHIVES OF DERMATOLOGY | Prognostic Factors in Primary Cutaneous Aplastic Large Cell Lymphoma | 2009 |
| Other Publication | LEUKEMIA & LYMPHOMA | Extranodal tural killer/T-cell lymphoma: current concepts in biology and treatment | 2009 |
| Other Publication | ONCOLOGY RESEARCH | Dymic CD8 T-Cell Responses to Tumor-Associated Epstein-Barr | 2009 |
| Other Publication | JOURL OF THE AMERICAN ACADEMY OF DERMATOLOGY | Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab | 2008 |
| Other Publication | Clinical advances in hematology & oncology : H&O | Evaluation and magement of angioimmunoblastic T-cell lymphoma | 2008 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin disease/lymphoma. | 2008 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. | 2008 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphomas. | 2008 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. | 2006 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. | 2006 |
| Other Publication | Jourl of the tiol Comprehensive Cancer Network | Magement of advanced stage Hodgkin lymphoma. | 2006 |
| Other Publication | ANLS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
| Other Publication | INVESTIGATIOL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
| Other Publication | Investigatiol New Drugs, | A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003) | 2005 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
| Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane alog | 2003 |
| Other Publication | Blood | Treatment of refractory | 1999 |
| Other Publication | Leukemia & lymphoma | Bevacizumab and cyclosphosphamide, doxorubicin | 2014 |
| Other Publication | Journal of clinical oncology | Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyte | 2014 |
| Other Publication | Blood | Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma | 2014 |
| Other Publication | Blood | Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades | 2013 |
| Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma | 2013 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Targeted Therapy in Relapsed Classical Hodgkin Lymphoma | 2013 |
| Other Publication | Blood | Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma | 2013 |
| Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma | 2013 |
| Other Publication | ANNALS OF ONCOLOGY | Efficacy of abbreviated Stanford V chemotherapy | 2013 |
| Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | The efficacy and tolerability of adriamycin, bleomycin | 2013 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally | 2013 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Risk of Therapy-Related Secondary Leukemia in Hodgkin Lymphoma | 2013 |
| Other Publication | BLOOD | Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma | 2013 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Bruton Tyrosine Kinase Inhibitor Ibrutinib | 2013 |
| Other Publication | BLOOD | Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma | 2012 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin | 2012 |
| Other Publication | ONCOLOGIST | Brentuximab Vedotin in Transplant-Naive Patients with Relapsed or Refractory Hodgkin Lymphoma | 2012 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Brentuximab Vedotin | 2012 |
| Other Publication | LEUKEMIA & LYMPHOMA | Cardiac toxicity associated with bevacizumab | 2012 |
| Other Publication | INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS | 2011 |
| Other Publication | CLINICAL CANCER RESEARCH | MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B | 2011 |
| Other Publication | LEUKEMIA & LYMPHOMA | Current concepts and controversies in the management of early stage Hodgkin lymphoma | 2011 |
| Other Publication | Hematology / the Education Program of the American Society of Hematolo | Optimal therapy of advanced Hodgkin lymphoma. | 2011 |
| Other Publication | Advani, R. H., Chen, H., Habermann, T. M., Morrison, V. A., Weller, E. | Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B | 2010 |
| Other Publication | EXPERT REVIEW OF ANTICANCER THERAPY | Risk stratification in extranodal natural killer/T-cell lymphoma | 2010 |
| Other Publication | Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, | Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes | 2009 |
| Other Publication | LANCET ONCOLOGY | Management of T-cell and natural-killer-cell neoplasms in Asia | 2009 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Phase I Study of the Humanized Anti | 2009 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Impact of positive positron emission tomography on prediction of freedom from progression after | 2007 |
| Other Publication | LEUKEMIA & LYMPHOMA | Angioimmunoblastic T cell lymphoma: Treatment experience with cyclosporine | 2007 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy | 2004 |
| Other Publication | Pediatric blood & cancer | ACR appropriateness Criteria® pediatric Hodgkin lymphoma. | 2014 |
| Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era | 2014 |
| Other Publication | ONCOLOGY-NEW YORK | ACR APPROPRIATENESS CRITERIA (R) Localized Nodal Indolent Lymphoma | 2013 |
| Other Publication | LEUKEMIA & LYMPHOMA | A multicenter phase II trial to determine the safety | 2013 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 1.2013 Featured Updates to the NCCN Guidelines | 2013 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphomas, version 1.2013. | 2013 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Gene Expression-Based Model Using Formalin | 2013 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's Lymphomas, version 3.2012. | 2012 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas, Version 3.2012 Featured Updates to the NCCN Guidelines | 2012 |
| Other Publication | PLOS ONE | Single Cell Profiling of Circulating Tumor Cells | 2012 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines | 2012 |
| Other Publication | RADIATION ONCOLOGY | Interim-treatment quantitative PET parameters predict progression | 2012 |
| Other Publication | BLOOD | In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 | 2012 |
| Other Publication | CLINICAL CANCER RESEARCH | A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed | 2012 |
| Other Publication | INVESTIGATIONAL NEW DRUGS | Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine | 2011 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin lymphoma. | 2011 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma | 2011 |
| Other Publication | BLOOD | Prediction of survival in diffuse large B | 2011 |
| Other Publication | OBSTETRICS AND GYNECOLOGY | Lymphoma in Pregnancy Initially Diagnosed as Vaginal Intraepithelial Neoplasia and Lichen Planus | 2011 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2011 |
| Other Publication | JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY | ACR Appropriateness Criteria (R) on Hodgkin's Lymphoma-Unfavorable Clinical Stage I and II | 2011 |
| Other Publication | SCIENCE TRANSLATIONAL MEDICINE | CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma | 2011 |
| Other Publication | Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, | Prediction of Survival In Diffuse Large B | 2010 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study | 2010 |
| Other Publication | CURRENT PROBLEMS IN CANCER | ACR Appropriateness Criteria (R): Follow-Up of Hodgkin's Lymphoma | 2010 |
| Other Publication | CLINICAL CANCER RESEARCH | Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed | 2010 |
| Other Publication | JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | Non-Hodgkin's Lymphomas | 2010 |
| Other Publication | Journal of the National Comprehensive Cancer Network | NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. | 2010 |
| Other Publication | BLOOD | Interim positron emission tomography scans in diffuse large B-cell lymphoma | 2010 |
| Other Publication | BRITISH JOURNAL OF HAEMATOLOGY | Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival | 2010 |
| Other Publication | CURRENT OPINION IN ONCOLOGY | The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma | 2009 |
| Other Publication | ARCHIVES OF DERMATOLOGY | Prognostic Factors in Primary Cutaneous Anapl | 2009 |
| Other Publication | Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., | Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR) | |
| Other Publication | CLINICAL LYMPHOMA & MYELOMA | Targeting CD40 in Waldenstrom's Macroglobulinemia | 2009 |
| Other Publication | LEUKEMIA & LYMPHOMA | Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment | 2009 |
| Other Publication | ONCOLOGY RESEARCH | Dynamic CD8 T-Cell Responses to Tumor | 2009 |
| Other Publication | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab | 2008 |
| Other Publication | Clinical advances in hematology & oncology : H&O | Evaluation and management of angioimmunoblastic T-cell lymphoma | 2008 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin disease/lymphoma. | 2008 |
| Other Publication | BLOOD | Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with | 2008 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. | 2008 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphomas. | 2008 |
| Other Publication | CANCER | Non-Hodgkin lymphoma of the breast | 2007 |
| Other Publication | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | Treatment of mantle cell lymphoma: Current approach and future directions | 2006 |
| Other Publication | ARCHIVES OF DERMATOLOGY | Staging accuracy in mycosis fungoides | 2006 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. | 2006 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. | 2006 |
| Other Publication | Journal of the National Comprehensive Cancer Network | Management of advanced stage Hodgkin lymphoma. | 2006 |
| Other Publication | ANNALS OF ONCOLOGY | A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833) | 2005 |
| Other Publication | INVESTIGATIONAL NEW DRUGS | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
| Other Publication | Investigational New Drugs, | A phase I trial of aprinocarsen (ISIS 3521/LY900003) | 2005 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Mitoxantrone, etoposide | 2004 |
| Other Publication | CLINICAL CANCER RESEARCH | Phase I and pharmacokinetic study of BMS-188797, a new taxane analog | 2003 |
| Other Publication | Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litc | A phase I trial of doxorubicin, paclitaxel | 2001 |
| Other Publication | Blood | Treatment of refractory | 1999 |
Years In Practice: 36 (started in 1989)
Accepts New Patients: Yes
Ranjana Advani, Other has not yet listed the medications that she commonly prescribes.
